Approved drugs for multiple sclerosis: the challenge of choice
暂无分享,去创建一个
[1] J. Lechner-Scott,et al. Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study , 2017, The Lancet Neurology.
[2] Xavier Montalban,et al. Treatment decisions in multiple sclerosis — insights from real-world observational studies , 2017, Nature Reviews Neurology.
[3] Jeffrey A. Cohen,et al. Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients , 2016, Neurology.
[4] G. Salanti,et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. , 2015, The Cochrane database of systematic reviews.
[5] Christian Confavreux,et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.
[6] Jeffrey A. Cohen,et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial , 2012, The Lancet.
[7] C. Polman,et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis , 2011, Multiple sclerosis.
[8] Georgia Salanti,et al. Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.
[9] J. Norrie,et al. Pragmatic Trials. , 2016, The New England journal of medicine.